1-3 of 3
Dima El-Sharkawi, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Outcomes of Phase I/II Clinical Trials for Patients with Relapsed/Refractory Haematological Malignancies: Experience of an Early Phase Clinical Trials Unit

Chin-Hin Ng, MD MRCP, FRCPATH, Dima El-Sharkawi, MD, Elspeth M Payne, MDPhD, Kwee L Yong, Kirit M Ardeshna, MD FRCP, FRCPATH, Asim Khwaja, FRCPath, Rakesh Popat
Journal: Blood
Blood (2016) 128 (22): 3613.
https://doi.org/10.1182/blood.V128.22.3613.3613
Published: 2016
Journal Articles

A Phase I Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the Muk Three Trial

Rakesh Popat, Sarah R Brown, Avie-Lee Tillotson, Fiona Collinson, Louise M Flanagan, Cathy D Williams, Kwee L Yong, Gordon Cook, MD PhD, Matthew W Jenner, MD, Martin Kaiser, Jim Cavet, FRCPath, Dima El-Sharkawi, MD, Chin-Hin Ng, MD MRCP, FRCPATH, Eric Low, Gareth J Morgan, MD PhD, Faith E Davies, MD
Journal: Blood
Blood (2016) 128 (22): 3321.
https://doi.org/10.1182/blood.V128.22.3321.3321
Published: 2016
Journal Articles

A Dose-Escalation (DE) Study with Expansion Evaluating Safety, Pharmacokinetics and Efficacy of the Novel, Balanced PI3K/mTOR Inhibitor PQR309 in Patients with Relapsed or Refractory Lymphoma

Graham P. Collins, MD PhD, Rakesh Popat, Anastasios Stathis, Fatime Krasniqi, MD PhD, Toby A. Eyre, MD, Chin Hin Ng, MD, Dima El-Sharkawi, MD, Christian Schmidt, MD, Andreas Wicki, MDPhD, Elena Ivanova, PhD, Debora Schmitz, PhD, Sasa Dimitrijevic, PhD, Martin H. Dreyling, MD PhD
Journal: Blood
Blood (2016) 128 (22): 5893.
https://doi.org/10.1182/blood.V128.22.5893.5893
Published: 2016